Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

paclitaxel

Bristol Myers Squibb logo

BMS’ oral maintenance therapy boosts survival in AML patients

Drug improved survival by almost ten months

Bristol Myers Squibb logo

Armed with new data, BMS plans filings for Celgene CAR-T liso-cel

Achieved a 53% complete response rate in study participants

- PMLiVE

Amgen raises forecasts after closing $13.4bn Otezla deal

Scope to build product further with ongoing trials in additional indications

Celgene building

UPDATED: BMS completes Celgene merger after FTC okay

Approval comes over ten months after acquisition announcement

- PMLiVE

Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day

First wave of new molecular entities has potential to generate 14 approvals

- PMLiVE

FDA advisors say no to empagliflozin in type 1 diabetes

Approval of Boehringer, Lilly-partnered drug expansion looks unlikely

- PMLiVE

Takeda divests over-the-counter and prescription drugs to Stada for $660m

Japanese pharma said it has plans to divest $10bn in non-core assests

- PMLiVE

Halozyme faces late-stage pancreatic cancer drug failure, cuts 55% of jobs

Will now focus on its novel drug delivery platform to drive business growth

Bristol Myers Squibb logo

BMS’ Opdivo stalls in Q3, but overall figures still top expectations

Group sales rose 6% to $6bn in the third quarter

- PMLiVE

Sanofi/Regeneron wins another EU approval for Dupixent

Becomes first biologic approved in EU for CRSwNP indication

- PMLiVE

Another day, another Brexit delay – so what happens now?

Health Secretary Matt Hancock maintains UK will retain regulatory collaboration with EMA

- PMLiVE

New hires at Amgen, Eli Lilly and Zosano

The latest movers in pharma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links